专注于癌症早期检测的生物科技公司MIRXES-B(02629.HK) 宣布订立配售协议,以每股32.5元配售约2,188.8万股新股,相当于经扩大后已发行股本的约7.34%。配售价较公告前最后交易日收市价折让约11.88%。此次配股预计筹集总额约7.11亿元,所得款项净额约为6.73亿元。公司计划将募集资金按以下比例分配:约30%用于投资及并购活动;约25%用于研究及开发(包括现有及新管线的临床...
Source Link专注于癌症早期检测的生物科技公司MIRXES-B(02629.HK) 宣布订立配售协议,以每股32.5元配售约2,188.8万股新股,相当于经扩大后已发行股本的约7.34%。配售价较公告前最后交易日收市价折让约11.88%。此次配股预计筹集总额约7.11亿元,所得款项净额约为6.73亿元。公司计划将募集资金按以下比例分配:约30%用于投资及并购活动;约25%用于研究及开发(包括现有及新管线的临床...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.